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Abstract
Aims/hypothesis Sphingolipid metabolism regulates beta cell biology and inflammation and is abnormal at the onset of type 1
diabetes. Fenofibrate, a regulator of sphingolipid metabolism, is known to prevent diabetes in NOD mice. Here, we aimed to
investigate the effects of fenofibrate on the pancreatic lipidome, pancreas morphology, pancreatic sympathetic nerves and blood
glucose homeostasis in NOD mice.
Methods We treated female NOD mice with fenofibrate from 3 weeks of age. The pancreatic lipidome was analysed using
MS. Analysis of pancreas and islet volume was performed by stereology. Islet sympathetic nerve fibre volume was
evaluated using tyrosine hydroxylase staining. The effect on blood glucose homeostasis was assessed by measuring
non-fasting blood glucose from age 12 to 30 weeks. Furthermore, we measured glucose tolerance, fasting insulin and
glucagon levels, and insulin tolerance.
Results We found that fenofibrate selectively increases the amount of very-long-chain sphingolipids in the pancreas of NOD
mice. In addition, we found that fenofibrate causes a remodelling of the pancreatic lipidome with an increased amount of
lysoglycerophospholipids. Fenofibrate did not affect islet or pancreas volume, but led to a higher volume of islet sympathetic
nerve fibres and tyrosine hydroxylase-positive cells. Fenofibrate-treated NOD mice had a more stable blood glucose, which was
associated with reduced non-fasting and increased fasting blood glucose. Furthermore, fenofibrate improved glucose tolerance,
reduced fasting glucagon levels and prevented fasting hyperinsulinaemia.
Conclusions/interpretation These data indicate that fenofibrate alters the pancreatic lipidome to a more anti-inflammatory and
anti-apoptotic state. The beneficial effects on islet sympathetic nerve fibres and blood glucose homeostasis indicate that
fenofibrate could be used as a therapeutic approach to improve blood glucose homeostasis and prevent diabetes-associated
pathologies.
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Sympathetic nerve fibres . Type 1 diabetes . Tyrosine hydroxylase
Abbreviations
GPL Glycerophospholipid
LPC Lysophosphatidylcholine
PC Phosphatidylcholine
PE Phosphatidylethanolamine
TH Tyrosine hydroxylase
Introduction
Experimental studies have demonstrated the importance of
sphingolipids in regulating beta cell biology and inflammation
[1, 2]. The central sphingolipid metabolite is ceramide, which
is generally considered to induce apoptosis and insulin
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resistance [3]. Diversity in sphingolipid structure is accom-
plished by adding headgroups to the hydroxyl group of cer-
amide and by varying the length of the acyl chain (C14–C26)
[4]. Adding a phosphocholine generates sphingomyelin,
which is a major component of myelin sheaths [5]. The addi-
tion of galactose and sulfate to ceramide forms sulfatide,
which is an insulin chaperone and regulator of insulin secre-
tion [6, 7]. Furthermore, C24 sulfatide is involved in regulat-
ing natural killer T cells by CD1d presentation [8].
Sphingolipids are also of interest as a major component of
the myelin sheath surrounding sympathetic nerves [9].
Sympathetic nerves are involved in the pathology of type 1
diabetes, with an observed loss of islet sympathetic nerve
fibres in individuals with newly diagnosed type 1 diabetes
[10] and NOD mice [11]. Sympathetic neurons inhibit insulin
and stimulate glucagon secretion to prevent hypoglycaemia
[12, 13]. The loss of pancreatic sympathetic nerve fibres is,
therefore, a contributing factor to the early loss of glucagon
secretion observed in adolescents with type 1 diabetes and
NOD mice [11, 14].
Another lipid class is the glycerophospholipids (GPLs),
which make up more than 50% of the lipids in plasma mem-
branes [15]. GPLs and their derivate lysoGPLs (lacking one or
both lipid chains) are important structural components that are
known to regulate cell biology and inflammation [15]; how-
ever, they are relatively undescribed in relation to type 1
diabetes.
We have previously shown that sphingolipid metabolism is
abnormal at the onset of type 1 diabetes, as evidenced by a
reduced islet level of sulfatide and reduced expression of sev-
eral enzymes involved in sphingolipid metabolism [16].
Furthermore, polymorphisms in genes involved in
sphingolipid metabolism are linked to the genetic predisposi-
tion to type 1 diabetes and to the degree of cellular islet auto-
immunity. In this regard, we have previously reported that
fenofibrate, a peroxisome proliferator-activated receptor alpha
agonist, increased islet sulfatide levels and completely
prevented diabetes in NOD mice, thereby making fenofibrate
a possible new therapy for type 1 diabetes [16].
Additional insight into the mechanisms of action of
fenofibrate is needed to better determine its therapeutic poten-
tial. Therefore, the aims of this study were to examine the
effects of fenofibrate on pancreas morphology and the
lipidome, and to evaluate its effects on blood glucose
homeostasis.
Methods
Animals Animal experiments were conducted in agreement
with Directive 2010/63/EU of the European Parliament and
of the Council of 22 September 2010 on the protection of
animals used for scientific purposes, and the Danish Animal
Experimentation Act (LBK 474 15/05/2014). The Danish
Animal Experiments Inspectorate (reference 2016-15-0201-
00841) and the local ethical committee (EMED: P 15-383, P
16-440 and P 18-408) approved the study.
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Female NOD mice (Taconic Biosciences, Hudson, NY,
USA) were housed at the Department of Experimental
Medicine (University of Copenhagen, Copenhagen,
Denmark) and kept in a specific pathogen-free animal facility
(temperature 22°C, 12 h light cycle, air changed 16 times per
hour and humidity 55 ± 10%). Three-week-old mice were ran-
domly distributed into two groups receiving either a standard
Altromin 1320 diet (Altromin, Lage, Germany) or a modified
Altromin 1320 diet containing 0.1% fenofibrate (Sigma, St
Louis, MO, USA). All mice had free access to food and drink-
ing water. There was no difference in body weight between the
two groups at the start of the experiment. Mice were treated
from the age of 3 weeks and until the experiment was termi-
nated. Diabetic mice were excluded from the study. Diabetes
diagnosis was based on two blood glucose measurements
>12 mmol/l with an interval of 2 days. Mice were weighed
each week, and food and water intake were measured weekly
by weighing the food racks and water flask, respectively.
Glucose monitoring was performed using FreeStyle Lite
(Abbott Diabetes Care, Alameda, CA, USA) by measurement
from the tail tip. Mice were put into individual cages and fasted
for 6 h from 08:00. Fasting serum insulin and glucagon levels
were measured using a Mercodia mouse insulin or glucagon
ELISA kit, respectively (Mercodia, Uppsala, Sweden). Fasting
insulin above 1000 pmol/l was defined as hyperinsulinaemia.
ITT and GTT Thirteen-week-old mice were fasted as described
above. Fasting blood glucose was measured from the tail tip
and used as time point 0 min.Mice were then, for the GTT, i.p.
injected with 0.01 ml of 1 mol/l glucose per g body weight.
Glucose concentrations were measured as described above at
time 15, 30, 45, 60, 90 and 120 min. Because of the difference
in fasted blood glucose between the groups, the results are
shown as the per cent increase in blood glucose compared
with the fasting blood glucose concentration of each mouse.
AUC was calculated using the fasting blood glucose level as
baseline. For the ITT, mice were i.p. injected with 0.75 U
insulin (Actrapid, Novo Nordisk, Bagsværd, Denmark) per
kg body weight. Glucose concentrations were measured at
time 15, 30, 45, 60, 90, 120 and 150 min. Results are shown
as the per cent change in blood glucose compared with the
fasting blood glucose concentration of each mouse. Glucose
concentrations declined for the first 60 min. An AUC for time
0–60 min was used as a measurement of insulin tolerance.
Glucose concentrations increased during the 60–150 min pe-
riod, and an AUC calculated with 60 min glucose as 100%
was used to measure the mice’s response to hypoglycaemia.
Organ weight, insulitis and stereology The mice were killed
and their organs were carefully removed and weighed.
Pancreases were fixed in 10% neutral buffered formalin over-
night until paraffin embedding. Pancreases were cut in 5 μm
sections in their entirety. For insulitis scoring, sections were
stained with H&E and evaluated using a BX53 microscope
(Olympus America, Melville, NY, USA). A total of 30 islets
from each mouse were scored blindly according to the follow-
ing scale: 0, no infiltration; 1, intact islets but with few mono-
nuclear cells surrounding the islets; 2, peri-insulitis (multiple
mononuclear cells surrounding the islets); 3, islet infiltration
below 50%; 4, islet infiltration above 50%. For images of the
different insulitis scores, see [17]. For stereological evaluation
of islet and pancreas volume, every 20th section was H&E
stained and scanned at ×10magnification using NanoZoomer-
XR (Hamamatsu, Hamamatsu City, Japan). The resulting im-
ages were investigated using newCAST software version
2019.02. (Visiopharm, Hoersholm, Denmark). A point-
counting grid with 25 intersections and 1 encircled unit inter-
sections was applied to the images, and they were counted
blindly for the total number of intersections touching islets
∑P(islet) and the total number of unit intersections touching
pancreases ∑P(pancreas).
For stereology analysis of sympathetic nerves, every 30th
section was stained for tyrosine hydroxylase (TH; ab112,
Abcam, Cambridge, UK; diluted 1:150) and H&E. Slides
were scanned at ×40 magnification and a point-counting grid
with 256 intersections was applied to the images, and they
were counted blindly for the total number of intersections
touching a TH-positive area∑P(TH). TH stainingwas divided
into two fractions, fibres and cells. Islet, pancreas or TH vol-
ume was estimated using the following equation based on the
Cavalieri method [18].
V ¼ T  a=p ∑P islet; pancreas; or THð Þ
Where V is the volume, a/p designates the area per point of
the grid and T specifies the section distance.
Immunofluorescence Pancreatic tissues were fixed as de-
scribed above and cut in 1.5 μm sections. Following
deparaffinisation and rehydration, the sections were rinsed in
PBS and treated with target retrieval solution citrate pH 6.1
(Dako, Ely, UK) for 30 min at 99°C, then cooled to room
temperature. Following a 5 min rinse in PBS, the sections
were blocked in 2% BSA and 0.05% Tween 20 in PBS for
30 min at room temperature. Guinea pig anti-insulin
(ab195956, diluted 1:800), rabbit anti-glucagon (ab92517, di-
luted 1:400) and sheep anti-TH (ab113, diluted 1:25) were
applied for 1 h at room temperature (insulin), 24 h at 4°C
(glucagon) or 48 h at 4°C (TH). The sections were then rinsed
twice in PBS and once in blocking buffer, each for 5 min.
Relevant secondary antibodies labelled with Cy3 (insulin,
ab102370, diluted 1:100), phycoerythrin (glucagon,
ab72465, diluted 1:100) or FITC (TH, ab6896, diluted
1:1000) were applied for 1 h at room temperature. All anti-
bodies were from Abcam. The sections were washed three
times, each for 5 min, mounted in Prolong Gold Antifade with
Diabetologia (2019) 62:2262–22722264
DAPI (Life Technologies, Carlsbad, CA, USA) and examined
using a Zeiss LM710 confocal microscope (Zeiss,
Oberkochen, Germany). For quantification, the slides were
scanned using a Zeiss Axio Scan.Z1 (Zeiss) and ten islets were
chosen randomly from each mouse (n = 6). For every islet, the
number of cells co-expressing hydroxylase and glucagon/
insulin were counted.
Lipid measurement For lipid measurement, 10 mg samples
were taken from the tail of the pancreas, snap frozen and kept
at −80°C until analysis. Samples were homogenised at 4°C on
TissueLyser II (QIAGEN, Hilden, Germany) in 155 mmol/l
ammonium bicarbonate. Total protein concentration was mea-
sured using the Pierce BCA Protein Assay (Thermo Fisher
Scientific, Waltham, MA, USA). Aliquots corresponding to
100 μg protein were subjected to lipid extraction by a modi-
fied Bligh and Dyer protocol executed at room temperature
[19]. The sample aliquots were spiked with 10 μl of 50 nmol
(corresponding to 0.5 pmol) of SHexCer 30:1:2 standard.
Quantification of sulfatide species was performed on a
(U)HPLC UltiMate 3000 RSLCnano System (Thermo
Fisher Scientific) interfaced online to the Q-Exactive
Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher
Scientific). We used a silica column 0.5 × 150 mm (YMC-
Pack Silica analytical column, 3 μm particles). We used
LipidXplorer version 1.2.7 (https://wiki.mpi-cbg.de/lipidx/
Main_Page) to extract data, selecting a time range based on
the eluted peaks of the sulfatide species. For the quantitative
shotgun lipidomics analysis, aliquots corresponding to 20 μg
of protein were subjected to lipid extraction by a modified
two-step Bligh and Dyer protocol executed on ice [20, 21].
The aliquots of tissue homogenate were spiked with 15 μl
internal lipid standard mix containing 30 pmol cholesteryl
ester 15:0-D7, 20 pmol ceramide 18:1;2/12:0;0, 10 pmol di-
acylglycerol 12:0/12:0, 20 pmol dihexose ceramide 18:1;2/12:
0;0, 25 pmol hexose ceramide 18:1;2/12:0;0, 25 pmol
lysophosphatic acid 17:0, 20 pmol lysophosphatidylcholine
(LPC) 10:0, 25 pmol lysophosphatidylethanolamine 13:0,
15 pmol lysophosphatidylglycerol 17:1, 20 pmol
lysophosphatidylinositol 13:0, 20 pmol lysophosphatidylserine
17:1, 25 pmol phosphatidic acid 12:0/12:0, 20 pmol phosphati-
dylcholine (PC) ether 18:1/18:1, 25 pmol PE 12:0/12:0, 15 pmol
phosphatidylglycerol 12:0/12:0, 15 pmol phosphatidylinositol 8:
0/8:0, 20 pmol phosphatidylserine 12:0/12:0 and 20 pmol
sphingomyeline 18:1;2/12:0;0. The combined two-step lipid ex-
tracts were subjected to MS analysis using a Q-Exactive
Quadrupole-Orbitrap Mass Spectrometer equipped with a
TriVersa NanoMate (Advion Biosciences, Ithaca, NY, USA).
Data processing was performed using LipidXplorer. All solvents
were HPLC-grade for lipid extraction and LC-MS grade for LC-
MS analysis.Methanol, water and chloroform for lipid extraction
were supplied by Rathburn (Walkerburn, UK). Water, methanol
and acetonitrile for LC-MSwere supplied byVWR (Radnor, PA,
USA). Ammonium bicarbonate was supplied by Sigma Aldrich
(Darmstadt, Germany).
Statistics Principal component analysis was performed using
R statistics software version 3.4.0 (R Development Core
Team, Vienna, Austria) and a p value of 0.01. The remaining
statistical analyses were performed using GraphPad Prism
version 7.0 (La Jolla, CA, USA). All data were assessed to
ensure equal variance and normal distribution between
groups. For comparisons between groups, a two-tailed un-
paired Student’s t test was used. To identify significantly al-
tered lipid classes a false discovery rate of 5% was used, as
determined by the two-stage linear step-up procedure of
Benjamini, Krieger and Yekutieli [22]. Data were log-
transformed before analysis if not normally distributed. If this
did not resolve the normality problem then a Mann–Whitney
U test was performed. Correlation analysis between neuronal
volume and the insulitis score was performed using linear
regression. The percentage of mice with hyperinsulinaemia
was evaluated using a χ2 test. A p value of less than 0.05
was considered significant. Data are shown as means ± SD
when a two-tailed unpaired Student’s t test was used and as
medians (interquartile range) when a Mann–Whitney U test
was performed. n denotes the number of animals used.
Results
Fenofibrate promotes the formation of very-long-chain
sphingolipids We previously showed how fenofibrate
prevented diabetes in NOD mice and how this was associated
with increased islet sulfatide levels, as evaluated by immuno-
histochemistry [16]. To further evaluate the effect of
fenofibrate on sulfatide levels, we employed an LC-MS ap-
proach. Female NODmice were again treated with fenofibrate
from the age of 3 weeks so as to precede the development of
insulitis starting at age 4 weeks [23]. The LC-MS analysis
showed an increase in the total amount of pancreatic sulfatide
(p = 0.0145; Fig. 1a). This was entirely due to an increase in
the amount of very-long-chain (≥20 carbons) C20:1, C24:0
and C24:1 sulfatide (p = 0.0017, p = 0.023 and p = 0.0008,
respectively; Fig. 1b). Next, we used a shotgun lipidomics
approach to evaluate the overall effect of fenofibrate on pan-
creatic lipids. The total amount of sphingomyelin was not
altered (Fig. 1c), although we did observe a significant in-
crease in very-long-chain C22:1 and C24:0 sphingomyelin
(p = 0.027 and p = 0.004, respectively; Fig. 1d). The total
amount of ceramide was also unaltered, but we found a
changed composition of ceramide species, with a decrease in
C16:0, C16:1 and C18:0 and an increase in C24:0 ceramide
(p = 0.047, p = 0.006, p = 0.001 and p = 0.006, respectively;
Fig. 1e, f).
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Increased levels of lysoGPLs Next, looking at the other lipid
classes identified in our shotgun approach, we noticed a large
variation within the control mice suggesting a loosely regulat-
ed pancreatic lipid metabolism in NOD mice (Fig. 2a). We
found clear signs of degradation of GPLs, as evidenced by
decreased levels of PC (p = 0.01), PC ether (p = 0.026) and
PE (p = 0.031) and a corresponding increase in LPC (p =
0.005), LPC ether (p = 0.01), lysophosphatidylethanolamine
(p = 0.013) and lysophosphatidylethanolamine ether (p =
0.04) in fenofibrate-treated mice (Fig. 2a). We also found in-
creased levels of lysophosphatidylglycerol (p = 0.009),
lysophosphatidylinositol (p = 0.002), lysophosphatidylserine
(p = 0.007), phosphatidic acid (p = 0.034) and cholesteryl es-
ter (p = 0.004). Furthermore, principal component analysis re-
vealed a clear distinction between the pancreatic lipidome of
control and fenofibrate-treated mice (Fig. 2b). LPC is the most
abundant lysoGPL, with saturated andmonounsaturated lipids
known to promote inflammation while polyunsaturated lipids
are anti-inflammatory [24]. We found increased levels of both
inflammatory and anti-inflammatory LPCs with fenofibrate
treatment. However, we found a significantly reduced ratio
of inflammatory to anti-inflammatory LPCs, suggesting that
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Fig. 1 Fenofibrate promotes the
formation of very-long-chain
sphingolipids. Pancreatic samples
taken from 13-week-old mice
were analysed by LC-MS to
evaluate (a) total sulfatide content
and (b) the amounts of individual
sulfatide species (as pmol/mg
protein). (c–f) The remaining
lipidome was analysed using a
shotgun lipidomics approach.
Results are presented as mol %.
(c) Total sphingomyelin, (d)
sphingomyelin species, (e) total
ceramide, (f) ceramide species.
White bars, control; grey bars,
fenofibrate. Data are shown as
means ± SD; n = 4. *p < 0.05;
**p < 0.01; ***p < 0.001 by two-
tailed unpaired Student’s t test
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fenofibrate promotes a more anti-inflammatory environment
(p = 0.029; Fig. 2c). In addition, we observed an increased
ratio of PC:PE with fenofibrate (p = 0.027; Fig. 2d), reflecting
improved membrane integrity [25]. A list of all identified lipid
species and their amounts can be found in the electronic sup-
plementary material (ESM) Table 1.
Fenofibrate prevents loss of pancreatic nerve fibres Next, we
sought to evaluate if the altered lipidome would be reflected in
altered pancreasmorphology. Pancreases from another set of 13-
week-old mice were analysed and showed that fenofibrate re-
duced insulitis to a similar degree as reported previously (ESM
Fig. 1) [16]. Stereology examination showed no difference in
pancreas or islet volume between control and fenofibrate-treated
mice (Fig. 3a, b). C24:0 sulfatide is found in both islets and
neuronal tissue, while C24:1 is primarily found in neuronal tis-
sue [26].We examined the neuronal volume in islets using TH, a
sympathetic neuron marker [10] (Fig. 3c, d). We found a higher
volume of islet sympathetic nerve fibres/islet volume (p = 0.048;
Fig. 3e) and a higher volume of TH-expressing cells in islets/
islet volume in fenofibrate-treated mice (p = 0.01; Fig. 3f). The
total TH volume/islet volume was also higher in the fenofibrate-
treated group (p = 0.005; Fig. 3g). There was an inverse corre-
lation between insulitis score and total islet TH volume/islet
volume (p = 0.01 and r2 = 0.5; Fig. 3h). To further understand
the nature of these cells, we performed immunofluorescence to
examine if the TH-positive cells co-expressed insulin or gluca-
gon. The immunofluorescence revealed that 30% of TH-
expressing cells also expressed insulin (TH-positive beta cells),
while 31% also expressed glucagon (TH-positive alpha cells)
(Fig. 3i, j).
There was no difference in pancreas or kidney weight be-
tween control and fenofibrate-treated mice, although we noted
a reduced spleen weight and increased liver weight associated
with liver hypertrophy in fenofibrate-treated mice (ESM Fig.
2), as described previously [27].
Fenofibrate improves blood glucose homeostasis Loss of
pancreatic sympathetic neurons is known to reduce glucose
tolerance in mice [28], so we investigated if the increased TH
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volume would be reflected in improved blood glucose homeo-
stasis. Non-fasting blood glucose was measured weekly from
age 12 to 30 weeks, and showed lower non-fasting blood
glucose in fenofibrate-treated mice than in the control group
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and (d) fenofibrate-treated 13-week old mice. Scale bars, 50 μm. Black
arrow, nerve fibre; red arrow, TH-positive cell. (e) Nerve fibre volume/
islet volume. (f) TH cell volume/islet volume. (g) Total TH volume (nerve
fibre and cell)/islet volume. (h) Correlation between insulitis score and
total TH volume/islet volume. (i) Image of a mouse islet with co-
immunofluorescence staining of TH (green), insulin (red) and DAPI
(blue). (j) Image of a mouse islet with co-immunofluorescence staining
of TH (green), glucagon (red) and DAPI (blue). Scale bars, 20 μm. Data
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(5.3 vs 6.1 mmol/l, p < 0.0001; Fig. 4a, b). Furthermore,
fenofibrate treatment resulted in more stable blood glucose,
as seen by the reduced SD (p = 0.024; Fig. 4c). Fasting blood
glucose was increased in the fenofibrate group vs the control
group (3.8 vs 3.1 mmol/l, p = 0.036; Fig. 4d). In addition, we
found lower fasting glucagon levels in fenofibrate-treated
mice (p = 0.019; Fig. 4e). Mice in the control group showed
signs of fasting hyperinsulinaemia (fasting insulin above
1000 pmol/l: 4/12 mice [33%]). This was not observed in
the fenofibrate-treated group (0/12 [0%], p = 0.03; Fig. 4f).
Next, GTTs showed that fenofibrate-treated mice had im-
proved glucose tolerance at age 13 weeks (p = 0.0002; Fig.
4g, h). Fenofibrate treatment did not induce any differences
in insulin sensitivity, as evaluated with ITTs (p = 0.62; Fig.
4i, j). However, the ITT did show that fenofibrate-treated mice
had an earlier return to normal glucose levels from insulin-
induced hypoglycaemia (p = 0.016; Fig. 4k).
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Fig. 4 Fenofibrate improves blood glucose homeostasis. (a) Blood glu-
cose levels were measured once a week under non-fasting conditions in
healthy NOD mice from age 12 to 30 weeks. (b) Quantification of non-
fasting blood glucose. (c) SD as a measurement of blood glucose stability.
(d–f) Mice were fasted for 6 h before blood sampling andmeasurement of
(d) blood glucose, (e) glucagon and (f) insulin levels.Mice with an insulin
level above 1000 pmol/l (dashed line) were defined as hyperinsulinaemic.
(g) GTTs were performed on healthy 13-week-old mice. Blood glucose
was measured at the indicated times. (h) AUC calculation for evaluation
of the GTT. (i) ITTs were performed on healthy 13-week-old mice and
blood glucose was measured at the indicated times. (j) AUC calculation
for the first 60 min (the decline period) of the ITT. (k) AUC calculation
for time 60–150 min (the incline period) of the ITT. White squares, con-
trols; black circles, fenofibrate-treated mice. Data are means ± SD, un-
paired two-tailed Student’s t test, in (a–j); medians with interquartile
range, Mann–Whitney U test, in (k). Control, n = 16; fenofibrate, n = 15
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in (g, h). n = 5 in (i–k). *p < 0.05. ***p < 0.001
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These effects were not the results of fenofibrate affecting
body weight, although fenofibrate-treated mice did have in-
creased water and food intake (ESM Fig. 3). Thus, fenofibrate
improves glucose homeostasis.
Discussion
A perturbed serum lipidome has been detected in children and
NODmicewho later develop type 1 diabetes [29, 30]. However,
there is a lack of studies looking at pancreas lipid composition in
relation to type 1 diabetes. We have previously shown that indi-
viduals with newly diagnosed type 1 diabetes have abnormal
islet sphingolipid metabolism. In this study, we sought to further
investigate the effects of fenofibrate, a regulator of lipid metab-
olism that has previously been shown to prevent diabetes and
inflammation in the pancreas of NODmice [16]. Using MS, we
found that fenofibrate treatment led to a specific increase in
very-long-chain sphingolipids, predominantly C24. We
observed no change in total ceramide levels, as the increase in
C24 was associated with a corresponding decrease in C16 and
C18. The altered chain length composition is critical, as the pro-
apoptotic properties of ceramide are greatly dependent on the
length of the lipid chain. C24 ceramide is an important compo-
nent of myelin sheaths with essential roles in neuronal [31] and
metabolic health [3, 32], whereas C16 ceramide promotes apo-
ptosis [33] and is associated with mitochondrial dysfunction and
insulin resistance [3, 34]. Hence, our results suggest that
fenofibrate creates a more beneficial ceramide composition in
the pancreas. The function of sulfatide is equally dependent on
lipid chain length, with C16 regulating insulin secretion and
proinsulin folding, while C24 is an immune regulator [35].
Furthermore, C24:1 sulfatide has been shown to induce
transcription of the gene encoding indoleamine 2,3-dioxygenase
1, an important regulator of autoimmunity with reduced expres-
sion in individuals with newly diagnosed type 1 diabetes [36,
37]. The increase in C24:0 and C24:1 sulfatide is, thus, likely to
create a more anti-inflammatory environment. This increase
might be a direct explanation for the diabetes-protective effect
of fenofibrate, as injections of C24:0 sulfatide have been shown
to reduce diabetes incidence in NOD mice [35].
The progression into diabetes is associated with decreased
levels of GPLs in NODmice [29], suggesting that the reduced
level of GPLs in fenofibrate-treated mice might be disadvan-
tageous. On the other hand, we found increased amounts of
lysoGPL, of which LPC is an inducer of insulin secretion [38].
The increased PC:PE ratio signals a changed membrane per-
meability, which could influence cytokine signalling; howev-
er, an increased ratio is also linked to endoplasmic reticulum
stress [39]. A limitation of this study is the lack of a ‘normal’
pancreatic lipidome from non-diabetic mice, thus making the
global biological effects of the observed changes hard to pre-
dict. It is difficult to find an appropriate control as different
mouse strains have very different pancreatic lipidomes. A re-
cent study found that the genetically closely related NOD-
SCID mouse (which does not develop diabetes) has a very
different pancreatic lipidome to the NOD mouse, making it a
bad model with which to compare [40]. We are therefore at
high risk of drawing different conclusions depending on
which mouse strain we define as ‘normal’.
There is also a lack of studies looking at the pancreatic
lipidome in humans, where studies have focused on blood
lipid content. Human studies have, in this way, found de-
creased sphingolipids and LPC levels in serum [30, 41].
However, the serum lipidome is a poor predictor of the pan-
creatic lipidome [40]. Studies looking at the pancreatic
lipidome across mouse strains and in humans are necessary
to understand how the observed fenofibrate-induced changes
inmicemight be related to the development of type 1 diabetes.
Mouse pancreatic islets are highly innervated by sympa-
thetic nerve fibres directly targeting alpha cells. In contrast,
human islets are only sparsely innervated, with most axons
contacting smooth muscle cells of blood vessels within the
islet [42]. Despite these differences, islet sympathetic nerve
fibres are lost in both NOD mice and individuals with type 1
diabetes [10, 11]. We observed a higher volume of TH-
positive nerve fibres and cells within the pancreatic islets of
fenofibrate-treated mice. The total TH volume was inversely
correlated with the insulitis score, as previously described
using the alternative sympathetic neuron marker neuropeptide
Y [11]. The higher nerve fibre volume is likely not a result of
neurogenesis, but rather of prevention of neural loss. This is in
line with studies describing how fenofibrate prevents loss of
nerves, as observed in diabetic retinopathy [43]. This might be
explained by sulfatide being present in pericytes in the choroid
layer, which regulate blood flow to the retina [44]. TH-
positive alpha and beta cells have previously been described
in mouse islets with a suggested role in beta cell development
[45]. TH is a commonly used neuronal marker; however, the
TH-positive cells in islets might be non-neural due to a lack of
co-expression with other neuronal markers [45]. Our results
suggest that the observed TH-positive cells in islets are a com-
bination of alpha (31%) and beta (30%) cells. The nature of
the remaining TH-positive cells is unknown; however, a sub-
set of delta cells has been shown to express TH [46].
All animal species have relatively stable non-fasting blood
glucose levels, also termed the glycaemic set point, and the set
point of one species might be life-threatening for other species
[47]. In this regard, it is interesting that fenofibrate seems to have
caused a shift in the glycaemic set point, with lower non-fasting
blood glucose and higher fasting blood glucose. This might be
caused by the increased volume of islet nerve fibres or changes in
alpha cell function, since these are known to influence the
glycaemic set point [47, 48]. Fenofibrate-treated mice had a
smaller difference in fasting to non-fasting blood glucose com-
pared with controls, which might explain the increased blood
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glucose stability. This would be beneficial as blood glucose
fluctuations are linked to an increased risk of diabetes-related
complications [49]. The improved glucose tolerance further
suggests overall improved blood glucose homeostasis, which
is supported by signs of reduced islet hyperactivity as evi-
denced by a reduced degree of hyperinsulinaemia and reduced
fasting glucagon levels. NOD mice are otherwise known to
suffer from hyperinsulinaemia [50]. The results also suggest
that fenofibrate might be beneficial in preventing hypo-
glycaemia, as fenofibrate-treated mice had an improved re-
sponse to insulin-induced hypoglycaemia. Taken together,
these results suggest that fenofibrate improves blood glucose
homeostasis by improving islet function, as no change in insu-
lin sensitivity was observed.
In conclusion, we have provided evidence that fenofibrate
treatment leads to remodelling of the pancreatic lipidome, with
increased levels of very-long-chain sphingolipids. This was asso-
ciated with an increased volume of sympathetic nerve fibres in
pancreatic islets and improved blood glucose homeostasis. These
results, together with our previous finding of fenofibrate
preventing and reversing diabetes in NOD mice, make
fenofibrate a possible therapeutic approach. Clinical trials are
needed to fully understand the therapeutic potential of fenofibrate.
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